Cargando…
Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy
OBJECTIVES: Neuro-inflammation is common in α-Synucleinopathies and Tauopathies; and evidence suggests a link between the tyrosine kinase Abl and neurodegeneration. Abl upregulates α-Synuclein and promotes Tau hyper-phosphorylation (p-Tau), while Abl inhibitors facilitate autophagic clearance. METHO...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308054/ https://www.ncbi.nlm.nih.gov/pubmed/25635231 http://dx.doi.org/10.4172/2155-9899.1000259 |
_version_ | 1782354540173983744 |
---|---|
author | Hebron, Michaeline L. Lonskaya, Irina Olopade, Paul Selby, Sandra T. Pagan, Fernando Moussa, Charbel E-H |
author_facet | Hebron, Michaeline L. Lonskaya, Irina Olopade, Paul Selby, Sandra T. Pagan, Fernando Moussa, Charbel E-H |
author_sort | Hebron, Michaeline L. |
collection | PubMed |
description | OBJECTIVES: Neuro-inflammation is common in α-Synucleinopathies and Tauopathies; and evidence suggests a link between the tyrosine kinase Abl and neurodegeneration. Abl upregulates α-Synuclein and promotes Tau hyper-phosphorylation (p-Tau), while Abl inhibitors facilitate autophagic clearance. METHODS: A model of α-Synucleinopathy harboring human mutant A53T α-Synuclein and exhibits concomitant increase in murine p-Tau was used to determine the immunological response to Abl inhibition. RESULTS: Age-dependent alterations of brain immunity, including loss of IL-10 and decreased levels of IL-2 and IL-3 were observed in old A53T mice. Brain CCL2 and CCL5 were decreased, but CX3CL1 remained constantly elevated. Young A53T mice exhibited differential systemic and central immune profiles in parallel with increased blood markers of adaptive immunity, suggesting an early systemic immune response. Tyrosine kinase inhibitors (TKIs), including nilotinib and bosutinib reduced brain and peripheral α-Synuclein and p-Tau and modulated blood immunological responses. TKIs did not affect brain IL-10, but they changed the levels of all measured blood immune markers, except CX3CL1. TKIs altered microglia morphology and reduced the number of astrocyte and dendritic cells, suggesting beneficial regulation of microglia. CONCLUSIONS: These data indicate that tyrosine kinase inhibition affects neuro-inflammation via early changes of the peripheral immune profile, leading to modulation of the neuro-immune response to α-Synuclein and p-Tau. |
format | Online Article Text |
id | pubmed-4308054 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
record_format | MEDLINE/PubMed |
spelling | pubmed-43080542015-01-27 Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy Hebron, Michaeline L. Lonskaya, Irina Olopade, Paul Selby, Sandra T. Pagan, Fernando Moussa, Charbel E-H J Clin Cell Immunol Article OBJECTIVES: Neuro-inflammation is common in α-Synucleinopathies and Tauopathies; and evidence suggests a link between the tyrosine kinase Abl and neurodegeneration. Abl upregulates α-Synuclein and promotes Tau hyper-phosphorylation (p-Tau), while Abl inhibitors facilitate autophagic clearance. METHODS: A model of α-Synucleinopathy harboring human mutant A53T α-Synuclein and exhibits concomitant increase in murine p-Tau was used to determine the immunological response to Abl inhibition. RESULTS: Age-dependent alterations of brain immunity, including loss of IL-10 and decreased levels of IL-2 and IL-3 were observed in old A53T mice. Brain CCL2 and CCL5 were decreased, but CX3CL1 remained constantly elevated. Young A53T mice exhibited differential systemic and central immune profiles in parallel with increased blood markers of adaptive immunity, suggesting an early systemic immune response. Tyrosine kinase inhibitors (TKIs), including nilotinib and bosutinib reduced brain and peripheral α-Synuclein and p-Tau and modulated blood immunological responses. TKIs did not affect brain IL-10, but they changed the levels of all measured blood immune markers, except CX3CL1. TKIs altered microglia morphology and reduced the number of astrocyte and dendritic cells, suggesting beneficial regulation of microglia. CONCLUSIONS: These data indicate that tyrosine kinase inhibition affects neuro-inflammation via early changes of the peripheral immune profile, leading to modulation of the neuro-immune response to α-Synuclein and p-Tau. 2014-09-30 /pmc/articles/PMC4308054/ /pubmed/25635231 http://dx.doi.org/10.4172/2155-9899.1000259 Text en Copyright: © 2014 Hebron ML, et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Article Hebron, Michaeline L. Lonskaya, Irina Olopade, Paul Selby, Sandra T. Pagan, Fernando Moussa, Charbel E-H Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy |
title | Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy |
title_full | Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy |
title_fullStr | Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy |
title_full_unstemmed | Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy |
title_short | Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy |
title_sort | tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in α-synucleinopathy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308054/ https://www.ncbi.nlm.nih.gov/pubmed/25635231 http://dx.doi.org/10.4172/2155-9899.1000259 |
work_keys_str_mv | AT hebronmichaelinel tyrosinekinaseinhibitionregulatesearlysystemicimmunechangesandmodulatestheneuroimmuneresponseinasynucleinopathy AT lonskayairina tyrosinekinaseinhibitionregulatesearlysystemicimmunechangesandmodulatestheneuroimmuneresponseinasynucleinopathy AT olopadepaul tyrosinekinaseinhibitionregulatesearlysystemicimmunechangesandmodulatestheneuroimmuneresponseinasynucleinopathy AT selbysandrat tyrosinekinaseinhibitionregulatesearlysystemicimmunechangesandmodulatestheneuroimmuneresponseinasynucleinopathy AT paganfernando tyrosinekinaseinhibitionregulatesearlysystemicimmunechangesandmodulatestheneuroimmuneresponseinasynucleinopathy AT moussacharbeleh tyrosinekinaseinhibitionregulatesearlysystemicimmunechangesandmodulatestheneuroimmuneresponseinasynucleinopathy |